Current Landscape of Pharmacotherapies for Sarcopenia

Buy Lab Tests Online


Super Moderator
Getting deep here, enjoyed this one!


Sarcopenia is a skeletal muscle disorder characterized by a progressive and generalized decline in muscle mass and function. Although it is mostly known as an age-related disorder, it can also occur secondary to systemic diseases such as malignancy or organ failure. It has demonstrated a significant relationship with adverse outcomes, e.g., falls, disabilities, and even mortality. Several breakthroughs have been made to find a pharmaceutical therapy for sarcopenia over the years, and some have come up with promising findings. Yet still no drug has been approved for its treatment. The key factor that makes finding effective pharmacotherapy so challenging is the general paradigm of standalone/single diseases, traditionally adopted in medicine. Today, it is well known that sarcopenia is a complex disorder caused by multiple factors, e.g., imbalance in protein turnover, satellite cell and mitochondrial dysfunction, hormonal changes, low-grade inflammation, senescence, anorexia of aging, and behavioral factors such as low physical activity. Therefore, pharmaceuticals, either alone or combined, that exhibit multiple actions on these factors simultaneously will likely be the drug of choice to manage sarcopenia. Among various drug options explored throughout the years, testosterone still has the most cumulated evidence regarding its effects on muscle health and its safety. A mas receptor agonist, BIO101, stands out as a recent promising pharmaceutical. In addition to the conventional strategies (i.e., nutritional support and physical exercise), therapeutics with multiple targets of action or a combination of multiple therapeutics with different targets/modes of action appear to promise greater benefit for the prevention and treatment of sarcopenia.


*In this article, we aimed to detail the complex pathophysiological pathway of sarcopenia, thereby outlining the possible targets or pathways for effective treatment (s). We review the completed and/or ongoing trials for pharmacological treatments so far and present future directions of therapeutic options.

2 Pathophysiology of Sarcopenia

Sarcopenia is a complex multifactorial geriatric syndrome. The underlying etiological factors and pathways are not fully understood. Both intrinsic factors within the muscle (e.g., apoptosis or autophagy) and systemic factors (e.g., hormonal changes and inflammatory status) can lead to the development of structural and functional deterioration in muscle[17–19]. The etiological factors of sarcopenia are detailed below (Fig. 1).

2.1 Imbalance in Muscular Protein Turnover
2.1.1 Muscle Protein Synthesis
2.1.2 Muscular Breakdown

2.2 Impaired Neuromuscular İntegrity

2.3 Changes in the Satellite Cells

2.4 Mitochondrial Dysfunction

2.5 Inflammation

2.6 Hormonal Changes

2.7 Renin–Angiotensin System (RAS)

2.8 MicroRNAs (miRNAs)

2.9 Dysbiosis

2.10 Behavioral Factors

3 Current Treatment of Sarcopenia

The basic treatment of sarcopenia at present depends on nonpharmacological strategies, i.e., exercise, optimum energy(calorie), protein intake/protein supplementation, and optimum intake of vitamin D and essential micronutrients[13, 118–121]. Resistance training is accepted as the most effective way to improve muscle mass and functions [118]. Likewise, aerobic training is also known for its beneficial effect in not only improving muscle mass and functions but also endurance and cardiovascular well-being [119].

Adequate protein, calorie, and vitamin D intake is essential to maintain muscle health. To prevent muscle loss, the recommended daily protein intake for healthy older adults is 1.0–1.2 g/kg body weight (BW), for older individuals with acute or chronic diseases it is 1.2–1.5 g/kg BW, and for older individuals with critical illness or malnutrition it is up to2.0 g/kg BW [120].
Vitamin D replacement is especially recommended for individuals suffering its deficiency since it is reported to improve muscle functions, falls, and mortality in older people with deficiency [121, 122]. The benefit of vitamin D supplementation on muscle functions has been reported, particularly in older women with very low vitamin D levels (< 25 nmol/L or < 10 ng/mL) and without over-supplementation (< 1000 IU/day) [121, 123]. Omega-3 (n3-polyunsaturated fatty acids; n3-PUFA) supplementation was also reported to be beneficial for muscle mass and volume, with more evident effects with higher doses (> 2g/day) [124]. Omega-3 may positively affect muscle protein synthesis response to anabolic stimuli, alleviating age-related anabolic resistance. It also seems to improve muscle strength and physical performance, although the evidence is conflicting and comes from meta-analysis with high protocol heterogeneity [125]. Selenium, magnesium, and inorganic nitrate have also been studied as dietary intake or supplements in clinical studies and appear to have a potential association with muscle performance and physical activity in older adults, but the evidence is limited compared with omega-3 [13, 126]. Creatine intake during resistance training is also suggested to increase the ability to exercise at high intensities and enhance post-exercise recovery and adaptation in older adults [124]. Overall, healthier diets of higher quality across adulthood are linked not only to lower risks of noncommunicable diseases like diabetes or cancer but also to the preservation of muscle mass and function [127]

4 Pharmacological Therapy of Sarcopenia

4.1 Hormonal Therapies

4.1.1 Testosterone

In summary, testosterone is the therapeutic agent embodying the richest evidence for improving muscle mass and strength, while worrisome adverse effects like increased cardiovascular events and prostate cancer should be considered especially with supraphysiologic doses. The ideal treatment regimen (dosage, formulation, and duration) promising the optimum risk-benefit balance between effectiveness and adverse effects of testosterone for older adults with sarcopenia is still under investigation.

4.1.2 Selective Androgen Receptor Modulators (SARMs)
Overall, although they were developed as alternative anabolic agents to testosterone due to safety concerns, the effects of SARMs on muscle still need to be solidified with further evidence. Therefore, long-term follow-up trials are needed to demonstrate the long-term safety and efficacy of SARMs.

4.1.3 Dehydroepiandrosterone (DHEA)
The positive effect of DHEA on sarcopenia components is inconclusive and needs to be elucidated by large-scale randomized controlled trials.

4.1.4 Estrogen‑Based Treatments and Selective EstrogenReceptor Modulators (SERMs)
In summary, estrogen-based therapies are not recommended to prevent or treat sarcopenia, due to conflicting and insufficient benefits on muscle mass and functions and their potential risks.
Nonetheless, further research is necessary to determine the efficacy of SERMs in adults with sarcopenia, since the current evidence is insufficient to support its use in sarcopenia (Table 1).

4.1.5 GH/IGF‑1/Insulin and Drugs For Type 2 Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia


Although it may have anabolic effects on muscle mass, the benefits on muscle functions have not been demonstrated to date. Moreover, its side effect profile raises concerns about its use with sarcopenia indication.

In summary, further clinical studies are needed to make firm conclusions on whether IGF-1 could be a safe and effective therapeutic strategy for sarcopenia.

Although it does not seem likely to be used for the treatment of sarcopenia in individuals without (due to the risk of hypoglycemia), insulin therapy in DM may be used to take advantage of its anabolic effect in muscles as well as hyperglycemia treatment. Nevertheless, it is clear that more work is needed to be more conclusive (Table 1).

Although metformin exhibits multiple pleiotropic effects on sarcopenia pathogenesis, available evidence regarding its effects on muscle health is contradictory. Further studies are needed to elucidate its role in the treatment of sarcopenia and whether its potential benefits outweigh its risks, considering its adverse effects on appetite and body weight.

Whether or not it is indicated for sarcopenia in the future, the use of GLP-1RA will require close monitoring and ensuring adequate protein intake in older adults in order not to lose the muscle reserve they already have (Table 1).

In summary, more studies are needed to determine whether SGLT-2i is beneficial especially in sarcopenic obesity and sarcopenic individuals without Diabetes Mellitus (Table 1).

Although the limited data available show that the positive effects of thiazolidinediones on muscle are not satisfactory, it is obvious that more studies are needed to make a clear claim (Table 1).

4.1.6 Ghrelin and Ghrelin Receptor Agonists
Indeed, ghrelin mimetics attracts attention as a therapeutic group that can be useful especially in catabolic conditions such as cancer cachexia, due to the effects on increasing LBM and total body weight. However, their effects on muscle functions are questionable, and more clinical studies are needed on their long-term efficacy and safety.

4.2 Myostatin and Activin II Receptor İnhibitors
In summary, among myostatin and activin II receptor inhibitors, bimagrumab stands out as an important therapeutic candidate, especially for sarcopenic obesity. Precise targeting seems to be more helpful in the case of developing myostatin-related drugs to narrow the spectrum of side effects [260].

4.3 Therapeutics with Actions on RAS
Further studies are needed to better clarify the effects of the agents for the classical RAS pathway on skeletal muscle (Table 1).

BIO101 is now considered to have the potential to become the first drug approved for the treatment of sarcopenia.

4.4 mTOR Inhibitors
There are a limited number of clinical trials on the effect of rapamycin or other rapalogs on muscle health in the literature, with findings showing that there is still a long way to go to elucidate whether this pathway can be used in the treatment of sarcopenia (Table 1).

4.5 Miscellaneous Drugs

Espindolol (MT-102) (S-isomer of pindolol)

It is clear that further large-scale studies are needed. That said, espindolol has the potential for use in cancer cachexia (Table 1).

AST-120 (renamezin)
This study shows that AST-120 (renamezin) has the potential to improve sarcopenia in patients with CKD, but should be supported with further evidence (Table 1).

Fast skeletal muscle troponin activators (FSTA)
Future studies will reveal whether this potential novel drug group will be an effective and safe choice for sarcopenia. At present, there is no ongoing trial studying the effects of FSTA on sarcopenia (Table 1).

Elamipretide (SS-31, MTP-131, Bendavia)
Thus, elamipretideis considered a novel class of drugs with potential for the treatment of sarcopenia (Table 1).

Anti-TNF therapy
Further studies will reveal whether anti-TNF therapy will get approval for the treatment of sarcopenia in the coming years (Table 1).

5 Challenges in the Development of Drugs for Sarcopenia and Future Directions

6 Conclusion

There has been an enormous effort to find an effective pharmacotherapeutic solution for sarcopenia over the last decades, and research still continues with some promising agents being in the current pipeline. Despite various therapeutic interventions being explored in a timely manner over the last decades, the effective options available against sarcopenia to date are still restricted to nutritional and exercise interventions. Among the drug candidates for sarcopenia, testosterone has the most accumulated evidence of anabolic effects on skeletal muscle and its safe profile in physiological doses. Bimagrumab (BYM338) is a promising drug candidate for especially sarcopenic obesity, showing dual effects of an increase in LBM and a decrease in fat mass. Ghrelin receptor agonists and espindolol are other promising drug groups for cancer cachexia with their reported beneficial effects on muscle mass and body weight. However, large-scale studies are needed. BIO101 is one of the most promising drug candidates in recent years with its positive effect on muscle functions in sarcopenic patients, and the results of its phase III trial will be followed with interest. The one lesson learned from so many years of experience in pharmaceutical trials is probably not to overlook the complexity and the fact that more than one mechanistic pathway is involved in the pathophysiology of sarcopenia. The multiple pathophysiological pathways probably create a “sarcopenia spectrum,” ending with individuals having different etiological factors underlying the same outcome (namely sarcopenia), and seem to generate different treatment needs depending on which etiological factor(s) and pathway(s) are dominant.

Analogous to sarcopenia, one can consider T2DM since it has also complex multifactorial pathogenesis similar to sarcopenia. Although all patients with T2DM are classified under the same diagnostic name, some present with insulin resistance and obesity, while some others present with weight loss and insulin deficiency, and accordingly they need different treatment strategies (weight loss with insulin sensitizers for the former group and insulin treatment and sometimes weight gain for the latter group) [223]. In the case of sarcopenia, as a simple example, one can expect different treatment strategies in patients with sarcopenia along with cancer and malnutrition than those having sarcopenia and obesity (sarcopenic obesity). Therefore, revealing which pathway is dominant in sarcopenia on an individual basis with more advanced future diagnostic methods and creating tailored treatment strategies will most probably be a breakthrough in the future of pharmacotherapy in sarcopenia. Novel therapeutics with more than one potential target of action or an approach of combining pharmacotherapies with other existing modalities (such as nutritional support and exercise) or emerging modalities appear to be more effective in obtaining promising results from ongoing and future drug trials.


  • gulistan-bahat-the-current-landscape-of.pdf
    1.6 MB · Views: 14
Defy Medical TRT clinic doctor


Super Moderator
Fig. 1 The pathophysiology of sarcopenia. *Fig. 1 was created with


Super Moderator
Fig. 2 Signaling pathways in sarcopenia and potential therapeutic agents targeting them. The blue and red arrows indicate promoting and inhibiting effects to the next step, respectively. 4EBP1 eukaryotic translation initiation factor 4E-binding protein 1, ACE angiotensin-converting enzyme, ACVR activin receptor type 2, Akt protein kinase B, ALK activin receptor-like kinase, AMPK AMP-activated protein kinase, ARB angiotensin type 1 receptor blocker, AT1R angiotensin type 1 receptor, BCAA branched-chain amino acids, GβL G proteinβ-subunit-like protein, GHSR growth hormone secretagogue receptor/ghrelin receptor, FOXO forkhead BOX O, FST follistatin (activin binding protein), IGF-1 insulin-like growth factor, IGFR insulin-like growth factor receptor, MASR mas receptor, MSTN myostatin, mTOR mammalian target of rapamycin, mTORC1 mammalian target of rapamycin complex 1, Nox2 NADPH oxidase II, p70S6K1 ribosomal protein S6 kinase 1, PDK phosphoinositide-dependent protein kinase,PI3K phosphoinositide 3-kinase, PIP2 phosphatidylinositol 45-bisphosphate, PIP3 phosphatidylinositol 345-trisphosphate, Raptorregulatory associated protein of mTOR, Rheb Ras homolog enriched in brain, ROS reactive oxygen species, SARMs selective androgen receptor modulators, Src non-receptor tyrosine kinase, TNFR1 tumor necrosis factor receptor 1, TNF-α tumor necrosis factor-α, TSC tuberous sclerosis complex


Super Moderator
Table 1 Pharmacotherapeutic options for sarcopenia: details on their target, action, benefits, adverse effects and concluding remarks
Screenshot (32923).png

Screenshot (32924).png

Screenshot (32925).png

Screenshot (32926).png

Screenshot (32927).png


Super Moderator
Key Points

*Currently, there is no approved pharmacological treatment for sarcopenia. Exercise and ideal nutritional intake covering optimal/adequate energy, protein, vitamin D, and other nutrients (in particular omega-3 fatty acids and essential micronutrients) are the mainstay of treatment.

*Complex multifactorial pathogenesis is one of the main reasons for the failure to find an effective pharmacotherapy for sarcopenia.

*Novel interventions or combination therapies that are able to concurrently act on multiple targets seem necessary to elicit an effective treatment for sarcopenia.

*Testosterone is the therapeutic agent with the most accumulated evidence regarding its anabolic effects on muscle and safety profile.

*The mas receptor agonist BIO101 is at the forefront of having the potential to be a therapeutic agent for sarcopenia.


Super Moderator
Take Home Messages

*Although many pharmacotherapeutic agents have been studied over the years, there is no approved drug for sarcopenia so far.

*Complex multifactorial pathogenesis of sarcopenia seems to be the major cause of disappointment encountered in the field of pharmacotherapies for sarcopenia. Novel therapeutics (single or in combination) with more than one potential target of action may finally enable pharmacological prevention or treatment of sarcopenia.

*Different molecules or pathways may be more prominent in the pathophysiology of age-related sarcopenia and in a variety of secondary sarcopenia subtypes. As in the treatment of many other diseases with complex/multifactorial pathogenesis (e.g., type 2 diabetes mellitus), individualized/tailored pharmacotherapy is expected to come to the fore in the context of sarcopenia in the coming years.


Seeker of Wisdom
Exercise and ideal nutritional intake covering optimal/adequate energy, protein, vitamin D, and other nutrients (in particular omega-3 fatty acids and essential micronutrients) are the mainstay of treatment.
Vitamin D supplementation not only doesn't work for sarcopenia, Vitamin D may actually have adverse effects on muscle health:

Available evidence does not support a beneficial effect of vitamin D supplementation on muscle health. Vitamin D may have adverse effects on muscle health, which needs to be considered when recommending vitamin D supplementation.

Vitamin D supplementation did not improve any sarcopenia indices in community-dwelling older adults and may compromise some aspects of physical performance.


Seeker of Wisdom
Omega-3 is also mostly bunk for this indication depending on which meta-analysis you think is more accurate:

In conclusion, our analyses indicated that n-3 PUFA supplementation may lead to very small increases in muscle strength but did not impact muscle mass and function in healthy young and older adults.

ω-3 fatty acid supplementation did not impact lean tissue mass (SMD 0.09 [-0.10, 0.28]). Benefits were observed for lower body strength (SMD 0.54 [0.33, 0.75]), timed-up-and-go (MD 0.29 [0.23, 0.35]s), and 30-s sit-to-stand performance (MD 1.93 [1.59, 2.26] repetitions) but not walking performance (SMD -0.01 [-0.10, 0.07]) or upper body strength (SMD 0.05 [-0.04, 0.13]). Supplementing with ω-3 fatty acids may improve the lower-body strength and functionality in older adults.


Super Moderator
Vitamin D supplementation not only doesn't work for sarcopenia, Vitamin D may actually have adverse effects on muscle health:

*In summary, the exact role of vitamin D supplementation in the prevention and treatment of sarcopenia remains uncertain due to the high heterogeneity of studies and the conflicting results of RCTs.

2 Nutritional intervention for sarcopenia

2.2. Vitamins​

2.2.1. Vitamin D Mechanisms

The vitamin D/VDR axis plays a key role in regulating biological processes central to sarcopenic muscle atrophy, such as proteolysis, mitochondrial function, cellular senescence, and adiposity (72). First, vitamin D deficiency appears to lead to increased muscle protein breakdown via the ubiquitin-proteasomal pathway (UPP) and autophagy and upregulation of AMPK and members of the renin-angiotensin system (73, 74). Second, permanent exit from the cell cycle (senescence) is a critical aging phenomenon, and the vitamin D/VDR axis has been shown to have regulatory control (75). Third, low vitamin D states may lead to impaired mitochondrial function (76), and active 1,25(OH)2D3 can increase oxygen consumption rates and fission/fusion dynamics (77, 78). Fourth, low vitamin D states may lead to increased adiposity in muscle (79), and those who are overweight have an increased risk of deficits in muscle mass and function (80). Clinical studies

Vitamin D is a fat-soluble vitamin synthesized in the skin, 90% of which comes from UV exposure and 10% from the diet. Vitamin D deficiency is now considered a global public health problem, and elderly individuals are at greater risk of vitamin D deficiency due to poor intestinal absorption, reduced sun exposure, and chronic renal insufficiency. Lower 25-(OH)-VD levels are thought to be associated with adverse changes in muscle mass and physical function (81). Yang et al. (82) fed mice a vitamin D-deficient diet for 24 weeks and immobilized them to determine the extent of skeletal muscle atrophy. As a result, vitamin D deficiency accelerated the decrease in gastrocnemius muscle mass, muscle fiber cross-sectional area, and grip strength; moreover, vitamin D supplementation inhibited the decrease in grip strength. The team also performed a cross-sectional analysis of 4,139 older adults, and linear regression analysis showed that serum 25 hydroxyvitamin D and physical activity were linearly associated and interacted with timed running time and grip strength. However, in another study in which the control group took a placebo daily and the intervention group took 800 IU of vitamin D orally daily, no differences were found between the two groups in leg push-up strength, function, or lean body mass after 1 year (83). According to the systematic reviews and meta-analyses, vitamin D supplementation alone did not improve muscle strength or SPPB scores, on the contrary, significantly decreased SPPB scores (84). When vitamin D was taken together with whey protein and leucine, the muscle mass of the limbs of patients with sarcopenia could be effectively increased even without physical exercise, and when combined with physical exercise, not only muscle mass increases but muscle strength and performance could also be significantly improved (85). However, we cannot be sure of the effectiveness of vitamin D supplementation alone, due to the presence of protein and amino acids. In summary, the exact role of vitamin D supplementation in the prevention and treatment of sarcopenia remains uncertain due to the high heterogeneity of studies and the conflicting results of RCTs.


Super Moderator
Omega-3 is also mostly bunk for this indication depending on which meta-analysis you think is more accurate:

*In conclusion, omega-3 fatty acids may improve sarcopenia, but well-designed, large prospective cohort studies and randomized controlled trials are needed to confirm these findings.

2.3. Omega-3 fatty acids​

Omega-3 fatty acids (also known as n-3 fatty acids) are polyunsaturated fatty acids with many potential health benefits and are available in three main dietary forms: alpha-linolenic acid (ALA; 18:3n-3), eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid (DHA; 22:6n-3). ALA is considered an essential fatty acid because it cannot be synthesized in the human body and is found in nuts, seeds, canola oil, etc. EPA and DHA are mainly found in fish oil.

2.3.1. Mechanisms

Skeletal muscle atrophy involves an inflammatory phase that leads to cell death and tissue remodeling and activates endoplasmic reticulum stress (ERS) and autophagy (96, 97). Both EPA and DHA potentially attenuate ERS and autophagy in skeletal muscles undergoing atrophy by attenuating the increase in PERK and ATG14 expression (98). In addition, DHA promotes mitochondrial biogenesis and skeletal muscle fiber remodeling (99) and delays muscle wasting by stimulating intermediate oxidative stress and inhibiting proteasomal degradation of muscle proteins (100).

2.3.2. Related studies

It has been proposed that elevated plasma levels of proinflammatory cytokines affect muscle catabolic and anabolic signaling pathways and thus may play a key role in the development and progression of sarcopenia, with data showing significantly elevated levels of IL-6 and TNFα in elderly Chinese individuals with sarcopenia (101). Therefore, reducing chronic inflammation associated with aging is emerging as a potential therapeutic target for sarcopenia, and NSAIDs may not be recommended for the treatment of sarcopenia due to the high risk of adverse events that may occur with their use in elderly individuals. Increasing evidence indicates that omega-3 polyunsaturated fatty acids reduce the expression of inflammatory genes and have anti-inflammatory activity (102), particularly eicosapentaenoic acid, docosahexaenoic acid, and alpha-linolenic acid. It was concluded from a systematic evaluation and meta-analysis that omega-3 fatty acid supplementation promotes lean body mass, skeletal muscle mass, and isometric contraction maximal muscle strength in the quadriceps (103). Dietary omega-3 fatty acid levels are negatively associated with sarcopenia (104), and more than 2 g/day of omega-3 fatty acids may increase muscle mass and improve walking speed, especially for those with sarcopenia who have been receiving the intervention for more than 6 months (105). However, linear regression analysis concluded that there was no association between plasma omega-3 levels and grip strength in older adults (106). When cancer patients were supplemented with omega-3 fatty acids, their muscle maintenance, quality of life, and body weight were not improved (107). According to expert opinions (108), doses of 3,000 mg/day DHA plus EPA or more (with preferably more than 800 mg/day EPA) may be required for positive physical performance in older adults (109, 110), because lower doses have no significant effects on muscle strength (111). In conclusion, omega-3 fatty acids may improve sarcopenia, but well-designed, large prospective cohort studies and randomized controlled trials are needed to confirm these findings.


Active Member
BIO101 is one of the most promising drug candidates in recent years with its positive effect on muscle functions in sarcopenic patients, and the results of its phase III trial will be followed with interest.
For anyone that's interested in it, BIO101 is 97% purity 20-hydroxyecdysone, which is available as a supplement. Recommended dosing:
Where it has been investigated, the effects are brought about by low μM concentrations of 20E, but to achieve maintained concentrations of this level in the plasma it is necessary that 20E should be supplied orally in large amounts (100–1000 mg) at least twice a day, because the bioavailability of 20E is poor and the half-life in the plasma is short.


Well-Known Member
Vitamin D supplementation not only doesn't work for sarcopenia, Vitamin D may actually have adverse effects on muscle health:

The two issues with these types of papers is that 1) many studies of Vitamin D did not include its key co-factors (Vitamins A K2 and E, at a minimum) and did not get blood levels up to around 50 which seems to be the "magic" level and 2) are not actionable since a healthy Vitamin D status is necessary for immune function at a minimum, and anything else it does can be considered a bonus. It's kind of like a study that said "good hydration does not reduce Male Pattern Baldness", to which the answer would be "so what, healthy hydration is still necessary". Regarding adverse effects, if we don't see problematic sarcopenia nearer the equator (which I don't believe we do) then it's likely not an issue.
Buy Lab Tests Online


bodybuilder test discounted labs
Defy Medical TRT clinic
nelson vergel coaching for men
Discounted Labs
cheap hcg viagra cialis
TRT in UK Balance my hormones
Testosterone books nelson vergel
Register on
Trimix HCG Offer Excelmale
Thumos USA men's mentoring and coaching
Testosterone TRT HRT Doctor Near Me
how to save your marriage

Online statistics

Members online
Guests online
Total visitors

Latest posts